Sees FY23 revenue up 1%-2%, consensus $15.2B. The company said, "Baxter expects sales growth of 1% to 2% on a reported basis and flat to 1% on a constant currency basis. The company expects U.S. GAAP earnings of $1.43 to $1.63 per diluted share and adjusted earnings, before special items, of $2.75 to $2.95 per diluted share. Guidance for 2023 reflects a challenging first half of the year due to increased cost of sales resulting from elevated costs of inventory produced in the second half of 2022, reflecting the significant inflationary pressures the company experienced, that will impact earnings when the related inventory is sold in 2023. Baxter expects the impact from these inflationary pressures on its earnings to begin to ease in the second half of the year. The benefits from the savings programs, which are in the process of being finalized, are expected to ramp over the course of the year, with the majority of the benefit being realized in the second half of the year. Finally, adjusted earnings guidance for 2023 also reflects incremental employee compensation costs, higher interest expense and an increased tax rate assumption as compared to full year 2022."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BAX:
- Baxter Crumbles as Projections Disappoint, Job Cuts Planned
- Notable companies reporting before tomorrow’s open
- Baxter price target lowered to $60 from $73 at KeyBanc
- Miromatrix MiroliverELAP timeline pushed out two or three quarters, says Piper
- Miromatrix Medical, Baxter enter research agreement for ALF